文献速递瓣膜外科

微创二尖瓣修复治疗交界区脱垂的安全性与长期疗效

Minimally invasive mitral valve repair for commissural prolapse: Safety, success, and long-term efficacy.
PubMed 文献 · Interdiscip Cardiovasc Thorac Surg · 2025-09-27

本研究回顾性比较34例交界区脱垂(CP)与590例后叶脱垂(PMLp)患者接受微创二尖瓣修复(MIMVR)的结果。CP组手术时间更长、住院更久,但短期结局与长期复发、再手术及生存率与PMLp组相当,表明MIMVR对CP安全、成功且持久。

要点

  • CP患者行MIMVR安全成功,长期疗效与PMLp相当。
  • CP组主动脉阻断和体外循环时间显著长于PMLp组。
  • CP组住院时间更长,但30天死亡率、卒中和ECMO支持无差异。

核心结论

  • MIMVR治疗交界区脱垂安全、成功且持久,结局与后叶脱垂相当。

研究设计与样本

  • 回顾性队列研究,2001至2022年单中心34例CP与590例PMLp患者接受MIMVR。

主要发现

  • CP组主动脉阻断时间127.0分钟 vs PMLp组105.0分钟(p=0.001),体外循环时间208.5分钟 vs 190.5分钟(p=0.031)。
  • CP组住院时间10.0天[8.0;12.0] vs PMLp组8.0天[7.0;9.0](p<0.001)。
  • 中位随访4.5年(CP)与2.4年(PMLp,p=0.001),两组复发MR、再手术及生存率相似。
  • 30天死亡率、卒中和ECMO支持等短期结局两组相当。

关键数值与推荐

  • 手术成功定义为免于转为瓣膜置换、胸骨切开及残余二尖瓣反流(MR)>I级。

临床怎么用

  • 对于交界区脱垂,MIMVR可提供与后叶脱垂相当的可靠修复效果,但需预期更长的手术时间和住院时间。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Commissural prolapse (CP) is a rare and complex mitral valve pathology which is complicated in preoperative diagnosis and repair. This study evaluated the safety, success, and long-term efficacy of minimally invasive mitral valve repair (MIMVR) for CP compared to posterior leaflet prolapse (PMLp). METHODS: Between 2001 and 2022, 34 patients with CP and 590 with PMLp underwent MIMVR at our center. Operative, perioperative, and long-term follow-up data were retrospectively collected. Surgical success was defined as freedom from conversion to valve replacement, sternotomy, and residual mitral regurgitation (MR) > grade I. Long-term efficacy included MR recurrence, reoperation, and survival. RESULTS: Median age was similar (CP: 64.0 years [53.2; 69.8] vs PMLp: 62.0 years [53.0; 69.0], p = 0.783). Barlow's disease was more frequent in PMLp (80.3% vs 32.4%, p < 0.001). Cross-clamp (127.0 min vs 105.0 min, p = 0.001) and bypass times (208.5 min vs 190.5 min, p = 0.031) were longer in CP. CP patients had longer hospital stays (10.0 days [8.0; 12.0] vs 8.0 days [7.0; 9.0], p < 0.001), but short-term outcomes, including 30-day mortality, stroke, and ECMO support, were comparable. At a median follow-up of 4.5 years (CP) and 2.4 years (PMLp, p = 0.001), rates of recurrent MR, reoperation, and survival were similar. CONCLUSIONS: MIMVR for CP is safe, successful, and durable with outcomes comparable to PMLp. Despite greater technical complexity and longer operative times, this approach provides reliable results for CP.

来源:Interdiscip Cardiovasc Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Engler C, Pölzl L, Nägele F, et al. Minimally invasive mitral valve repair for commissural prolapse: Safety, success, and long-term efficacy. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 41014492. doi:10.1093/icvts/ivaf213

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。